Absci
Absci is a generative AI drug creation company that combines AI with synthetic biology to discover and develop novel biologics. The company's platform designs and validates new drug candidates, specifically antibodies, with the goal of increasing the success rate and speed of drug discovery.
Brand Authority Index (BAI): 72/100
Archetype: Challenger
Category: Biotechnology
Part of: Independent
https://optimly.ai/brand/absci
Last analyzed: April 10, 2026
Verified from Absci website
Founded: 2011
Headquarters: Vancouver, Washington, USA
Buyer Intent Signals for Absci
Problems this brand solves
- Traditional Wet-Lab Discovery: Internal R&D teams attempting to identify antibody candidates using traditional wet-lab trial and error.
- CROMO Biology Services: Hiring specialized contract research organizations to perform traditional drug discovery services.
- Legacy Data Management: Managing discovery data via spreadsheets and legacy local databases without AI integration.
Buyers search for
- generative AI for antibody discovery
- de novo protein design companies
- AI drug creation platform
- best AI biotech stocks
- AstraZeneca AI discovery partner